Skip to main content
Fig. 11 | Journal of Translational Medicine

Fig. 11

From: Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation

Fig. 11

A schematic representation illustrating the role of sirolimus and rosuvastatin in preventing neointimal hyperplasia (created using BioRender). IL-6 interleukin 6, IL-1β interleukin 1 beta, TNF-α tumor necrosis factor alpha, Akt a protein cloned from the v-akt oncogene of retrovirus AKT8, mTOR mammalian target of rapamycin, STAT3 signal transducer and activator of transcription 3, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells

Back to article page